Compugen (CGEN) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Conference overview

• H.C. Wainwright covers over 650 companies and hosted the session, emphasizing its broad sector expertise.

• The session featured a presentation by the President and CEO, focusing on advancements in cancer immunotherapy.

Strategic pipeline and partnerships

• Two clinical programs, COM701 (anti-PVRIG) and COM902 (anti-TIGIT), are fully owned and advancing.

• Strategic partnerships with Gilead and AstraZeneca validate the platform and expand the pipeline.

• AstraZeneca's rilvegostomig, derived from COM902, targets over $5 billion in peak annual revenue.

• A $30 million milestone from Gilead and a $92 million cash balance support operations into 2027.

Scientific and clinical insights

• COM701 is the first clinical anti-PVRIG antibody, with clinical data presented and further validation from industry interest.

• COM902 is designed as an Fc-reduced antibody to enhance safety and efficacy, avoiding immune-related adverse events.

• Recent TIGIT studies show benefit mainly in PD-L1 high patients, and antibody Fc status is critical for tolerability.

• Triple combination therapy (PVRIG, TIGIT, PD-1) is positioned to address hard-to-treat, PD-1 non-responsive tumors.